



LINDEN<sup>7</sup>

Contact: Laura Bolch  
312-506-5663  
lbolch@lindenllc.com

FOR IMMEDIATE RELEASE: May 16, 2011

## **HYCOR Expands Board of Directors**

Linden Recruits Senior Executives from Quest and Abbott to Support HYCOR's Growth

---

GARDEN GROVE, Calif., – HYCOR Biomedical Inc., a leading manufacturer and marketer of in vitro diagnostic products for the global allergy, autoimmune and urinalysis markets, together with owner Linden LLC, today announced the appointments of Vijay Aggarwal, Ph.D. and James Koziarz, Ph.D., to its Board of Directors.

“We are thrilled to welcome Drs. Aggarwal and Koziarz to our growing team at HYCOR and are confident that they will have an immediate and meaningful impact at our company,” commented Richard Novak, Chairman of HYCOR’s Board of Directors and Operating Partner at Linden LLC. “Each of these gentlemen brings unique and seasoned perspective to our Board, and I am confident HYCOR will benefit from their guidance and insight.”

Dr. Aggarwal brings over 30 years of experience and leadership in the pharmaceutical and clinical diagnostics industries to HYCOR. He has served in senior management and director positions for a number of public and privately held companies, including Quest Diagnostics, IBT Laboratories, and SmithKline Beecham. Dr. Aggarwal will support HYCOR and its management team in a variety of capacities as Director, with a particular focus on channel development in clinical laboratories.

Dr. Koziarz joins HYCOR’s Board after a distinguished 25 year career at Abbott Laboratories, where he held several senior management and executive positions, including Corporate Vice President for Diagnostic Products Research & Development. Dr. Koziarz is also an active advisor to several venture-backed life sciences companies. Dr. Koziarz will focus his



collaboration with HYCOR and its management team on next generation assay and platform development strategies for global customers.

“We are pleased to have the opportunity to partner with these two leaders in clinical diagnostics and are confident their leadership will benefit HYCOR and the healthcare professionals and patients our products serve,” said HYCOR CEO Dick Aderman, formerly of Roche Diagnostics and Boehringer Mannheim. “Our executive team has already begun working with each of them on key initiatives currently underway at our company and we look forward to the value they will bring to our business.”

**About HYCOR Biomedical, Inc.**

Founded in 1981, HYCOR is a global manufacturer and marketer of in vitro diagnostics products. Since its founding, HYCOR has expanded its presence into urinalysis, allergy and autoimmune products used in clinical laboratories, hospitals and doctors’ offices worldwide. Among its products, HYCOR markets the HYTEC™, KOVA® and AUTOSTAT™ brands. The company is focused on delivering products that provide the highest value to clinicians through innovation, reliability and customer service. For more information, please visit [www.hycorbiomedical.com](http://www.hycorbiomedical.com).

**About Linden LLC**

Linden is a Chicago-based private equity firm focused exclusively on leveraged buyouts in the healthcare and life science industries. Linden's strategy is based upon three elements: i) healthcare and life science industry specialization, ii) integrated private equity and operating expertise, and iii) strategic relationships with large corporations. Linden's portfolio includes BarrierSafe Solutions International, Behavioral Centers of America, Corpak MedSystems, Drayer Physical Therapy Institute, HYCOR Biomedical, and Ranir. For additional information, please visit [www.lindenllc.com](http://www.lindenllc.com).

###